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Samuel Aparicio1,2* and Elaine Mardis3*The term heterogeneity covers many aspects of the vari-
ability in tumor phenotypes, which are a characteristic
of human malignancies. Morphologists of the late 19th
century first described the multiple cell types composing
tumors and began to recognize cancers of different types.
Over the past half century the molecular underpinnings of
the variability in human cancers has been gradually re-
vealed but within the last 5 years there has been an explo-
sion in our ability to determine and learn from cancer
heterogeneity, through the use of next-generation sequen-
cing and related methods. The complexity and variation in
the structure of cancers can seem daunting, but important
lessons in cancer biology and the approaches to therapy
can be learned from studying how much of the complexity
is subject to change and how much is a consequence of
stochastic rather than deterministic processes. The evolu-
tion of clones, individual variation in response to therapy,
distinct biological subtypes of cancer and tumor immune
responses are all examples of the heterogeneous nature of
human cancers. Self evidently, when heterogeneity is used
to describe any aspect of a cancer, it is important to know
which variational feature is being addressed.
Experimental approaches to heterogeneity
A review by Hiley et al. [1] sets the stage for the research
studies of heterogeneity published in this special issue,
by updating the reader regarding how the use of next-
generation sequencing and clever experimental design
have increased our understanding of genomic and re-
gional heterogeneity in cancers. The special collection
provides several research-based studies of tumor hetero-
geneity, encompassing the variation between individuals
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dinal study of single patient (‘N of 1’) cases (Fisher et al.
[3], Nadauld et al. [4]). These studies provide contrasts be-
tween the approaches needed to determine disease group-
ings in populations, where many hundreds or thousands
of patients must be studied, with the approaches to pursu-
ing the moving target of individual cancers. The latter can
be effectively studied in smaller numbers with informative
consequences when evolution is used to sift the features
undergoing selection and fixation. An Opinion piece by
Good et al. [5] provides a scientific and philosophical per-
spective on the N of 1 paradigm.Methodological approaches to heterogeneity
Of equal importance to the experimental approaches
used to study heterogeneity are the methods used to
evaluate heterogeneity across the spectrum of variation
that can be measured in cancer by different assay types.
These encompass next-generation sequencing methods
for analyzing tumor and normal cell composition, the
analysis of clonal populations in cancers (Qiao et al. [6]),
and methods addressing epigenetic plasticity (Zheng et al.
[7]). Hence, several important tools and approaches are
presented that facilitate answering critical questions about
heterogeneity, and an opinion piece contributed by
Russnes et al. [8] advocates for data integration to better
interpret heterogeneity data.Single cell approaches to heterogeneity
Resolving structure and function with single cell ap-
proaches is also becoming important, both in studies
of clonality as well as for functional assessment of tumor
cell populations. Learning how to reconcile whole tumor
cell-based population approaches with the single cell data
will be important. Nicholas Navin’s review [9] of single cell
sequencing in cancer studies provides a survey of this rap-
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Next-generation sequencing-based studies of RNA popu-
lations from cancer cells are revealing important aspects
of transcriptional activity and its role in cancer. A review
by Patrick Nana-Sinkam and Carlo Croce [10] sets the
stage by discussing the role of microRNAs in gene regula-
tion in cancers. White et al. [11] present important new
descriptions of long non-coding RNAs (lncRNAs) in lung
cancers, and Wyatt et al. [12] describe transcriptomes in
the context of therapy response in high-risk prostate can-
cers. The method for detecting allele-specific expression
contributed by Mayba et al. [13] will also yield important
insights into which variants detected by DNA sequencing
are actually being expressed in the transcriptome of
cancer cells. The role of the epigenome in contributing
to the patterning of transcriptomes and the possibility
of modulating RNA expression is emphasized in three
primary research articles exploring this aspect of tumor
heterogeneity (Lund et al. [14] , Fleischer et al. [15], and
Charlton et al. [16]).
Clinical aspects of heterogeneity
As our underlying knowledge about cancer genomics
and heterogeneity improves, the need to translate this in-
formation into informed cancer care for patients is an ob-
vious next step. Berger and Varghese have contributed an
Opinion piece [17] to describe the translation of cancer
genomics in the clinic, and contributions from de Bono
[18] and Bardelli [19] outline the use of circulating tumour
cells (CTCs) and circulating free DNA (cfDNA), respect-
ively, as approaches to monitoring tumor progression.
These blood-based or ‘liquid biopsy’ approaches present
an exciting new paradigm in contrast to conventional and
less sensitive imaging-based approaches to monitor pa-
tients. Deininger also reviews [20] an important area to
clinical therapeutics that is often identified by genomic in-
formation, providing an overview of therapy response and
resistance to targeted therapies. The genomic variability
between patients is highlighted in the research article of
Ali et al. [2], delineating molecular subtypes in large co-
horts of breast cancer patients.
Data and more data
Finally, in the genomic era, sharing of data and complete
descriptions of analytic methods, to the level of providing
code in addition to data, will prove crucial to continued
success. Boutros et al. [21] provide a novel look at crowd-
sourcing algorithms for cancer analysis, and Bartha
Knoppers and colleagues [22] present a critically import-
ant Opinion regarding the legal framework for genomic
data sharing. Hence, the special collection provides a
wide-ranging overview of cancer heterogeneity in its
many manifestations, from fundamental methods-based
approaches to study heterogeneity to the use of genomicinformation for response and progression monitoring.
We think the breadth of cancer studies that have been
impacted by next generation sequencing, including im-
proved understanding and characterization of cancer het-
erogeneity, is setting the stage for major breakthroughs in
our biological understanding of this vexing and compli-
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